Grounded in technology developed at the University of California, Santa Barbara, Cynvenio Biosystems, Inc. is a molecular diagnostics technology company developing tools to enable the early detection, longitudinal monitoring and targeted treatment of cancer. The company’s approach focuses on specialized molecular insights gleaned from rare cells to identify and characterize their pathology. Cynvenio has developed and deployed the LiquidBiopsy® system: a purpose-built automated rare cell isolation platform which leverages enhanced immunomagnetic capture within a patented microfluidic chip to recover rare cells from a simple blood draw. LiquidBiopsy is a powerful new front-end to develop real-time patient insights via next generation sequencing and molecular characterization techniques. The company is advancing the vision of personalized medicine by developing high performance instruments and assays that support the R&D market in life sciences. The firm's proprietary instrumentation, sample handling, cell sorting, detection, and amplification technology enables the work of organizations focusing on cancer research, stem cells and the discovery and validation of novel therapeutic solutions. The firm’s liquid biopsy testing technology is om he forefront of enabling more affordable and clinically actionable precision medicine strategies for cancer patients. Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third-party diagnost
